



08-14-02

162
8/21/02
AUG 19 2002
TECH CENTER 1600/2900

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
1662/54903

RECEIVED

Application Number
10/000,428

Filing Date
Nov. 30, 2001

Examiner
To be
Assigned

Art Unit
1621

Invention Title
CRYSTALLINE VENLAFAXINE BASE AND NOVEL
POLYMORPHS OF VENLAFAXINE HYDROCHLORIDE,
PROCESSES FOR PREPARING THEREOF

Inventor(s)
DOLITZKY et al.

Address to:
Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C. 20231,
on

Date 8/12/02

Signature

KENYON & KENYON

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the following reference to the attention of the Examiner. This reference is listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge **Deposit Account No. 11-0600** for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 8/12/02

By:

Siu K. Lo
Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

EL 82825/66345



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 01662/54903	SERIAL NO. 10/000,428
	APPLICANT DOLITZKY et al.	
	FILING DATE November 30, 2001	GROUP 1621

RECEIVED
AUG 19 2002
TECH CENTER 1600/2900

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB- CLASS	FILING DATE*
	4,611,078	Sept. 9, 1986	Husbands et al.			

* - if pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/32555	June 8, 2000	PCT			N/A	

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		J.P. Yardley, et al., 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity, Journal of Medicinal Chemistry, 1990, 33, pp. 2899-2905

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	